Drugs / MG1113
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03855696 | Jan 2019 → Jun 2021 | hemophilia | Green Cross Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05493631 Comparator | Aug 2022 → Dec 2024 | hemophilia | GC Biopharma Corp | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG1113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03855696 ↗ |
| Action | Inhibit | “Anti-tissue factor pathway inhibitor (TFPI)” NCT03855696 ↗ |
| Modality | Protein / enzyme biologic | “Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody” NCT03855696 ↗ |
| Route | Subcutaneous | “by SC injection” NCT03855696 ↗ |
| Target | TFPI | “Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody” NCT03855696 ↗ |